Vetbiolix aims to develop innovative products for treatment and prevention of diseases affecting Pets.
As pharmaceutical and biotech companies research novel molecules and compounds for human medicine, tests in different species often reveal exciting possibilities for pets. Vetbiolix has developed a unique approach focused on turning this potential into innovative prescription medicines and care products for pets. Because, surprisingly, veterinarians have few therapeutics and real preventive care products at their disposal that have been specifically developed and approved for pets.
Along with a virtual VetBiotech organization, Vetbiolix focus exclusively on clinical development of prescription medicines, diagnostic, nutraceuticals and care products for pets thanks to qualified external R&D partners in Europe & US.
Vetbiolix is passionate about giving veterinarians, and their clients, science-driven therapeutic & preventive options
3 products in Oncology,
& CARE PRODUCTS
3 products in Ophthalmology,
2 products in Oncology
Want to participate in our investment opportunities ?
Can-Fite Enters Projected $3 Billion Veterinary Osteoarthritis Market: Signs Agreement with Vetbiolix for Development of Piclidenoson for Pets
Lille, 28th June 2021
Can-Fite PETACH TIKVA, Israel, June 28th, 2021 — Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced it has signed a development and commercialization agreement with Vetbiolix, a France-based veterinary biotech company, for the development of Piclidenoson for the treatment of osteoarthritis in companion animals including dogs and cats.
Vetbiolix will have the exclusive right to Piclidenoson in the veterinary osteoarthritis market for two years, during which time Vetbiolix will conduct proof-of-concept studies and cover all associated costs. If the studies yield positive data and Vetbiolix exercises its option to obtain the license from Can-Fite, then Vetbiolix will be obligated to pay Can-Fite upfront and milestone payments, in addition to royalties on sales upon regulatory approval for veterinary use.
The canine osteoarthritis market is projected to reach $3billion by 2024. According to Grand View Research, the broader global companion animal health market is estimated at a value of $20 billion in 2021 and is expected to grow to $27 billion by 2028.
Current treatments for canine osteoarthritis include oral non-steroidal anti-inflammatory drugs (NSAIDs) which only treat symptoms and carry significant harmful side effects, and an injectable disease modifying osteoarthritis drug (DMOAD) that targets the progression of the disease. Piclidenoson, an oral drug that has a favorable safety profile in humans and in animal studies, offers a potentially safe and effective oral treatment for canine osteoarthritis.
Vetbiolix strengthens its pipeline with the SOLUDOTS-Paclitaxel product licensed from CARLINA Technologies for the veterinary oncology market
Lille, 08th July 2020
Vetbiolix, a French-based veterinary biotech company announced today
having entered into a worldwide, exclusive license and research agreement with CARLINA Technologies, a French-based contract service-based biotechnology company specialized in the development of nanomedicines to enter clinical development phase of SOLUDOTS-Paclitaxel for the
treatment of cancer in companion animals.
This agreement extends the veterinary oncology portfolio of Vetbiolix which currently includes a lateral flow assay development program to monitor cancer in companion animals, as well as others drug development programs in complex and age-related diseases affecting pets. The collaboration with CARLINA Technologies, a renowned expert in the development controlled-release formulations of medicines for human and animal health, is projected to advance the program into veterinary clinical development phases of development within 6 months.
SOLUDOTS-Paclitaxel is an improved version of the anticancer product TaxolTM, that showed improved antitumor activity over TaxolTM in human lung and ovary cancer models in mice. Preclinical safety evaluation antitumor in mice and rats have showed that SOLUDOTS-PTX was 10-fold less toxic than TaxolTM. SOLUDOTS-PTX is well tolerated in dogs at equivalent TaxolTM clinical dose used un humans without premedication.
Rapidly growing adoption of dogs and cats, because of improving economic status of people coupled with increasing pet healthcare expenditure, will drive the pet cancer therapeutics market in the coming years. Pet cancer therapeutics market accounted for USD 145 million in 2016 and is anticipated to reach USD 320 million in 2024, growing at a CAGR of 10.4% over the forecast timeframe. Rising incidences of cancer in dogs and cats, the growing awareness about cancer among their owners, and increasing specialization of vetenarians in oncology will drive chemotherapy drugs market which currently remains the gold standard treatment with surgery and radiotherapy. Pet chemotherapy drugs market accounted for USD 100.2 million in 2016 and is anticipated to reach USD 190.7 million in 2024, growing at a CAGR of 9.1% over the forecast timeframe.